3Cassell GH, Cole BC.Mycoplasmas agents of human disease. N Engl J Med, 1981,304 : 80-86.
4George S. Brainstem and striatal encephalitis complicating mycoplasma pneumoniae pneumonia : Possible benefit of intravenous immunoglobulin. Pediatr Infect Dis, 2001,20(5) : 543- 545.
5Kai M, Kamiya S, Yabe H, et al. Rapid detection of mycoplasma pneumoniae in clinical samples by the polymerase chain reaction.J Med Microbiol, 1992, 38(3) :166- 168.
6Terri B, Mark H.Azithromycin prophylaxis during a hospital outbreak of mycoplasma pneumoniae pneumonia. J Infect Dis, 2001, 183 : 907- 909.
7Vasilos LV, Rumel NB, Shchuka SS. Chemotherapeutic effectiveness of erythromycin, rifampicin and tetracyclines in chlamydiosis and mycoplasmosis in children. Antibiot Chemother, 1995, 40(6) : 40- 42.
7Arnold FW, Summersgill JT, LaJoie AS, et al. A worldwide per-spec- tive of atypical pathogens in community-acquired pneumoni -a[ J ]. Am J Respir Cfit Care Med,2007,175 (10) : 1086 - 1093.
8Eun BW, Kim NH, Choi EH, et al. Mycoplasma pneumoniaeinKorean children : The epidemiologyofpneumoniaoveranl8-yearperiod [ J ]. J Infect,2008,56(5 ) :326 - 331.
9Youn YS, Lee KY, Hwang JY, et al. Difference of clinical featuresin childhood Mycoplasma pneumoniae pneumonia[ J]. BMC pediatr, 2010,10:48.
10Chaudhry R,Nisar N, Hora B, et al. Expression and immuno-logical characterization of the carboxyl terminal region of the PIadhesin pro- tein of mycoplasma pneumoniae [ J ]. J C lin Mi-cmbiol,2005,43 ( 1 ) : 321.
